West Lafayette-based Inotiv forms partnership to focus on liver disease therapies

WEST LAFAYETTE, Ind. (Inside INdiana Business) — West Lafayette-based Inotiv Inc. (Nasdaq: NOTV) is partnering with a Japanese biopharmaceutical company to bolster Inotiv’s drug discovery research services for treatments of liver disease.

The Indiana company says it will use PhoenixBio Co. Ltd’s proprietary PXB-mouse research model.

According to the National Institute of Health, the mice are called chimeric or “humanized” because the livers contain human cells. The company says the model is a liver-humanized chimeric model used for drug discovery and early development.

Inotiv, which recently changed its name from Bioanalytic Systems Inc., says the collaboration enhances its expertise in conducting research for a variety of hepatic, or liver, diseases.

“We’re excited to provide research services, lend our expertise, and play a role in fulfilling the need for a more advanced, effective way of evaluating new therapies using PhoenixBio’s proprietary model,” said Kelly Long, senior director of Pharmacology & Toxicology at Inotiv.

PhoenixBio says the partnership will result in new technologies to help pharmaceutical and biotechnology companies to create effective therapies for liver disease.